摘要:
Disclosed are β-D-ribofuranosyl-pyrazolo[3,4-d]pyrimidine compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Representative compounds include those having the general formula.
摘要:
Disclosed are methods for treating hepatitis C viral infections using deaza-purine compounds of Formula I: wherein W, W1, W2, Y, R1, Z, Y′ and R are as defined herein.
摘要:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, Y, W, W1 and W2 are as defined herein.
摘要:
Disclosed are methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W1, W2, Y, R1, Z, Y′ and R are as defined herein.
摘要:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W1, W2, Y, R1, Z, Y′ and R are as defined herein.
摘要:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, T, Y, W, W1 and W2 are as defined herein.
摘要:
Disclosed are methods and intermediates for the preparation of 7-(2′-R1-substituted-β-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such 7-(2′-substituted-β-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds are represented by Formula I as follows: wherein, each of R1, R2, and R3 are as defined herein.
摘要:
Disclosed are 6-hydroxyamino- or a 6-alkoxyamino-7-deazapurine-ribofuranose derivatives, salts, pharmaceutical compositions, and methods of use thereof for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.